JP Morgan Downgrades Kala Pharmaceuticals to Underweight, Announces $1.5 Price Target

JP Morgan analyst Christopher Neyor downgrades Kala Pharmaceuticals (NASDAQ:KALA) from Neutral to Underweight and announces $1.5 price target.

JP Morgan analyst Christopher Neyor downgrades Kala Pharmaceuticals (NASDAQ:KALA) from Neutral to Underweight and announces $1.5 price target.

Total
0
Shares
Related Posts